Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism

NCT02064439 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT02064439
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02064439 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism
Lead sponsor
Bayer
Phase
Phase 3
Overall status
Completed
Start date
March 5, 2014
Completion date
November 4, 2016
Enrollment
3,365 (actual)
Sites
266

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary embolism, thromboembolism, thrombosis, venous thromboembolism, venous thrombosis